Payment overview · 2025
General Payments
$296.42
15 reported records · 5 companies
Healthcare provider profile · identity verified
Bria Hull, FNP-C
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · PARKERSBURG, WV · NPI 1205209475
Verified facts
What the public records show
CMS Open Payments records show Bria Hull, FNP-C received $296.42 in general payments during 2025 across 15 reported records.
Novo Nordisk Inc accounted for 55.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $163.55 | 55.2% | 8 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $54.30 | 18.3% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $38.48 | 13.0% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $20.14 | 6.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $19.95 | 6.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $296.42 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $83.34 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $83.34 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $54.30 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $38.74 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $38.48 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $38.48 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $20.14 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $19.95 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 51 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
38 | 13 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
51 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 377 | 130 |
| Levothyroxine Sodium | Levothyroxine Sodium | 225 | 82 |
| Amlodipine Besylate | Amlodipine Besylate | 209 | 84 |
| Losartan Potassium | Losartan Potassium | 192 | 65 |
| Lisinopril | Lisinopril | 190 | 73 |
| Metformin Hcl | Metformin Hcl | 158 | 57 |
| Metoprolol Succinate | Metoprolol Succinate | 157 | 57 |
| Hydrochlorothiazide | Hydrochlorothiazide | 141 | 44 |
| Pantoprazole Sodium | Pantoprazole Sodium | 136 | 52 |
| Omeprazole | Omeprazole | 134 | 48 |
| Escitalopram Oxalate | Escitalopram Oxalate | 102 | 26 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 100 | 39 |
| Duloxetine Hcl | Duloxetine Hcl | 92 | 29 |
| Simvastatin | Simvastatin | 87 | 32 |
| Pravastatin Sodium | Pravastatin Sodium | 82 | 27 |
| Mounjaro | Tirzepatide | 66 | 23 |
| Jardiance | Empagliflozin | 62 | 25 |
| Allopurinol | Allopurinol | 61 | 16 |
| Eliquis | Apixaban | 61 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 60 | 19 |
| Sertraline Hcl | Sertraline Hcl | 60 | 21 |
| Atenolol | Atenolol | 58 | 21 |
| Doxycycline Hyclate | Doxycycline Hyclate | 52 | 40 |
| Ozempic | Semaglutide | 51 | 14 |
| Gabapentin | Gabapentin | 50 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 49 | 20 |
| Meloxicam | Meloxicam | 49 | 13 |
| Montelukast Sodium | Montelukast Sodium | 48 | 19 |
| Tamsulosin Hcl | Tamsulosin Hcl | 39 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 38 | 14 |
| Synthroid | Levothyroxine Sodium | 38 | 13 |
| Trazodone Hcl | Trazodone Hcl | 37 | 15 |
| Spironolactone | Spironolactone | 36 | 11 |
| Carvedilol | Carvedilol | 35 | 13 |
| Furosemide | Furosemide | 34 | 17 |
| Metformin Hcl Er | Metformin Hcl | 34 | 15 |
| Potassium Chloride | Potassium Chloride | 34 | 17 |
| Trulicity | Dulaglutide | 32 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 31 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 31 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 31 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 29 | 13 |
| Torsemide | Torsemide | 29 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 27 | 26 |
| Citalopram Hbr | Citalopram Hydrobromide | 27 | suppressed |
| Glimepiride | Glimepiride | 27 | 12 |
| Januvia | Sitagliptin Phosphate | 26 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 26 | suppressed |
| Prednisone | Prednisone | 26 | 23 |
| Buspirone Hcl | Buspirone Hcl | 25 | suppressed |
| Ezetimibe | Ezetimibe | 25 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 24 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 24 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 24 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 24 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 23 | suppressed |
| Valsartan | Valsartan | 23 | suppressed |
| Finasteride | Finasteride | 22 | suppressed |
| Ibuprofen | Ibuprofen | 22 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 22 | 11 |
| Famotidine | Famotidine | 21 | suppressed |
| Bupropion Xl | Bupropion Hcl | 20 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Glipizide Er | Glipizide | 18 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 18 | suppressed |
| Nifedipine Er | Nifedipine | 18 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Felodipine Er | Felodipine | 16 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 15 | suppressed |
| Methocarbamol | Methocarbamol | 14 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $296.42 · 15 records | Novo Nordisk Inc | Cologuard Collection Kit, Dexcom G6 Transmitter, Ozempic, QULIPTA, Rybelsus, TRELEGY ELLIPTA, UBRELVY, Wegovy | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error